ClinicalTrials.gg
RecruitingNCT07622043Updated Aug 20, 2026

Effectiveness of Two Different Desensitizing Dental Varnishes

An interventional study of Fluoride-containing varnish and Fluoride-free varnish in Dentin Hypersensitivity and Dentin Desensitizing Agents, sponsored by Ivoclar Vivadent AG. Recruiting at 1 site in Liechtenstein. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Ivoclar Vivadent AG · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Dental varnishes are commonly used to relieve dentin hypersensitivity by forming a protective film that occludes dentinal tubules and reduces fluid flow. This clinical investigation aims to compare the desensitizing effect of a fluoride containing varnish with a fluoride free placebo varnish. Primary and secondary objectives include evaluating short and long term reductions in dentinal hypersensitivity, assessing patient reported outcomes and daily experiences, and monitoring the varnish's tolerability and safety.

02

Conditions studied

  • Dentin Hypersensitivity
  • Dentin Desensitizing Agents

Browse trials for

03

In context

Dentin Sensitivity

288 studies on the registry are indexed under Dentin Sensitivity; 46 are open to participants now.

This study's planned enrollment of 66 is close to the median of 60 across 279 interventional studies indexed under Dentin Sensitivity.

Browse Dentin Sensitivity studies →

Lead sponsor

Ivoclar Vivadent AG is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed by the subject
  • Age: 18-65 years
  • assessment scale ≥ Grade 2 in
  • two non-neighboring teeth in different quadrants
  • The affected teeth are/have: vital, caries-free, received no restorations within the last month
  • No change in medication anticipated over the next 3 months (e.g. due to upcoming surgery etc.)

Exclusion criteria

Exclusion Criteria:

  • and limitations of the MD as described in the instructions for use.
  • Known or allergy to the device material (especially acrylates, mint flavouring)
  • Pregnant or other vulnerable subjects
  • Participants with severe systemic disease
  • Enrolment of employees of the dental clinic of Ivoclar Vivadent AG
  • Recent change in medication concerning Analgesics, NSAIDs, psychotropic drugs, other medications that may alter pain perception
  • Intake of analgesics prior to appointment
  • Professional desensitizing therapy in the last 3 months
  • Bleaching procedures in the last 4 weeks
  • Confounding dental conditions at test sites: defective or extensive restorations, abutment teeth for prostheses, recent restorations, pulpitis/periapical pathology.
  • Current or recent use of desensitizing toothpastes or mouthrinses (i.e. products specifically marketed for the treatment of dentin hypersensitivity) within 4 weeks prior to enrolment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Fluoride-containing varnish

    A fluoride-containing varnish is applied to a tooth that is hypersensitive.

    Device: Fluoride-containing varnish

  • Placebo comparator
    Fluoride-free varnish

    A fluoride-free varnish is applied to a tooth that is hypersensitive.

    Device: Fluoride-free varnish

Interventions

  • DeviceFluoride-containing varnish

    A fluoride-containing varnish is applied to a tooth that is hypersensitive.

  • DeviceFluoride-free varnish

    A fluoride-free varnish is applied to a tooth that is hypersensitive.

06

What researchers measure

Primary outcomes

  1. Change of dentin hypersensitivity

    assessed by patient response to an air stimulus using a pain scale (grades 0-4, lower scores mean a better outcome)

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
  • Internal Clinic Ivoclar Vivadent AG
    Schaan, 9494, Liechtenstein
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2027, 9 months after the start.

Of 33 industry-sponsored interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's planned 9 months is above that.

Counting every sponsor, half of 144 studies reached it within 6 months; a quarter within 3 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Aug 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07622043
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jul 13, 2026
Primary completion
Apr 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion